Overweight post prostate cancer surgery patients have greater chance of cancer recurrence

NewsGuard 100/100 Score
After prostate cancer surgery, obese men are more likely than men with normal weight to have high levels of prostate specific antigen (PSA), a marker for cancer recurrence, according to a study led by Johns Hopkins researchers.

"Our results show that moderately and severely obese men were at an increased risk for high PSA levels after surgery and therefore are likely to have prostate cancer recurrence," said Stephen Freedland, M.D., instructor of urology at the Brady Urological Institute at Johns Hopkins and lead researcher of the study.

The study involved 1,106 patients treated at five Veteran's Administration and active military hospitals across the country. Moderately and severely obese patients -- defined as those having a body mass index (BMI) of greater than 35 kilograms per square meter, or the equivalent of a 5-foot-10 inch man weighing 245 pounds or more -- were found to have several indicators of aggressive prostate cancer, including higher Gleason scores and rising PSA levels after surgery. Men with a BMI of greater than 35 kg/m2 had a 60 percent risk of cancer recurrence within three years. Thirty-one percent of African-American men in the study were obese, while 21 percent of Caucasian men were obese.

"Our findings add to the burgeoning list of chronic and deadly diseases associated with obesity and underscore the importance of this major public health problem," says Freedland.

Obesity is an independent predictor of biochemical failure following radical prostatectomy. Stephen J. Freedland, William J. Aronson, Christopher J. Kane, Joseph C. Presti, Christopher L. Amling, David Elashoff, Martha K. Terris.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels